Eli Radiopharma announces Series A of almost €54M to advance cancer and neurological radiopharmaceuticals
Eli Radiopharma announces Series A of almost €54M to advance cancer and neurological radiopharmaceuticals
Issuer confirms completed Series A of almost €54M (ECB-converted estimate, not an exact disclosed sum). Huagai Capital leads with Bayland co-leading. Proceeds target preclinical validation, trials and IND filings; no approved therapy, commercial revenue or valuation disclosed. Date denotes China issuer announcement; US wire is Nov 11 ET.